Atrial Fibrillation – Landscape & Forecast – Disease Landscape & Forecast (G7)

Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF can lead to blood clots, increasing the risk of stroke fivefold. Pharmacological treatment includes rate control therapies (e.g., beta blockers, calcium channel blockers, digoxin), rhythm control therapies (class Ic and class III antiarrhythmics), and stroke prevention agents (e.g., vitamin K antagonists, direct-acting oral anticoagulants [DOACs]). Several key AF drugs will lose patent protection during the forecast period. Novel agents that are in clinical trials to treat AF include Novartis’s abelacimab and BMS / Johnson & Johnson Innovative Medicine’s milvexian. We expect these drugs to launch during the forecast period and fulfill some of the unmet needs that remain in AF treatment.

Questions answered

• What are the key drivers and constraints in the AF therapy market? How will current therapies perform over the forecast period?
• What do key opinion leaders think about emerging therapies such as milvexian and abelacimab? How will emerging therapies impact existing stroke prevention therapies?
• How will the genericization of the DOACs affect the market?
• What are the key unmet needs in AF treatment, and how likely will they be met during the forecast period?

Geography: United States, France, Germany, Italy, Spain, the United Kingdom, and Japan

Primary research: 19 country-specific interviews with thought-leading cardiologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalent cases of AF by country,; paroxysmal, persistent, and permanent diagnosed prevalent cases.

Forecast: 10-year, annualized, drug-level sales and patient share of key AF therapies through 2034, segmented by brands / generics as well as paroxysmal, persistent, and permanent diagnosed prevalent cases.

Drug treatments: Coverage of key current and late – phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.